Graves disease is behind much of adult hyperthyroidism, yet the pattern is anything but uniform. In a large US health system, age standardized prevalence was 0.34 percent in 34 per 10,000, while across the same country hyperthyroidism incidence in adults is estimated at about 1 to 2 percent per year with Graves occurring far more often in women. The most striking divide comes after diagnosis too, with thyroid eye disease in about 25 percent of patients and severe eye involvement in about 5 percent, plus pregnancy related risk that rises alongside TRAb levels.
Key Takeaways
- In the United States, the annual incidence of hyperthyroidism is estimated at about 1–2% per year among adults, with Graves disease accounting for the majority of cases
- Graves disease occurs about 7–8 times more often in women than in men
- Graves ophthalmopathy occurs in about 25% of patients with Graves disease and is severe in about 5%
- In pregnancy, Graves disease can cause fetal/neonatal thyrotoxicosis risk; TRAb levels above guideline thresholds correlate with higher risk
- In a systematic review, smoking increased the risk of Graves ophthalmopathy by about 2–3x compared with non-smokers
- TRAb positivity is reported in ~90% or more of patients with Graves disease in clinical series, supporting its role as a key disease marker
- Antithyroid drugs require ongoing lab monitoring; guideline-based schedules imply recurring lab costs measured per monitoring interval
- A US Medicare study reported that total costs for Graves disease management were substantial and included medication, outpatient visits, and laboratory monitoring
- In a claims-based analysis, patients with hyperthyroidism/Graves incurred higher all-cause healthcare costs than matched controls, with differences measured in dollars per patient-year
- A Cochrane review reported that continuing antithyroid drugs longer increases remission probabilities compared with shorter courses, with relapse reduced in longer-duration strategies
- Radioactive iodine therapy is associated with long-term euthyroidism in many patients; studies commonly report ~80% needing eventual levothyroxine within years due to hypothyroidism
- Radioactive iodine dose regimens typically achieve effectiveness with single or adjusted dosing; trial evidence reports high rates of thyrotropin suppression resolution
- European Thyroid Association guidelines recommend TRAb measurements for assessment of remission and relapse risk after antithyroid drugs
- Imaging with radioactive iodine uptake or thyroid scintigraphy helps confirm diagnosis when antibody testing is inconclusive; uptake patterns differentiate Graves from other causes
- Ultrasound with Doppler can show increased vascularity in Graves disease; clinical guidance cites this as supportive evidence
Graves disease affects about 0.34% of people in the US, mostly women, and drives common eye and thyroid complications.
Related reading
01 · Category
Epidemiology9 stats
01
In the United States, the annual incidence of hyperthyroidism is estimated at about 1–2% per year among adults, with Graves disease accounting for the majority of caseshttps://www.ncbi.nlm.nih.gov/books/NBK279114/
02
Graves disease occurs about 7–8 times more often in women than in menhttps://www.ncbi.nlm.nih.gov/books/NBK482369/
03
Graves ophthalmopathy occurs in about 25% of patients with Graves disease and is severe in about 5%https://www.ncbi.nlm.nih.gov/books/NBK448011/
04
Pretibial myxedema occurs in about 1–2% of patients with Graves diseasehttps://www.ncbi.nlm.nih.gov/books/NBK482368/
05
Age-standardized prevalence of Graves disease in a large US health system cohort was reported at 0.34% (34 per 10,000)https://pubmed.ncbi.nlm.nih.gov/28778469/
06
Incidence rates of hyperthyroidism show a seasonal pattern, with more diagnoses in winter months in some populations studiedhttps://pubmed.ncbi.nlm.nih.gov/25917890/
07
In a Swedish nationwide registry study, the standardized incidence ratio for hyperthyroidism peaked in the 45–54 age group, consistent with Graves disease predominance in adultshttps://pubmed.ncbi.nlm.nih.gov/23116566/
08
A Danish register-based cohort study reported Graves disease incidence around 30–40 per 100,000 person-yearshttps://pubmed.ncbi.nlm.nih.gov/26608202/
09
In a Taiwanese nationwide study, Graves disease incidence was reported at approximately 42 per 100,000 person-years (adjusted)https://pubmed.ncbi.nlm.nih.gov/23347460/
Interpretation
Epidemiology Interpretation
From an epidemiology standpoint, Graves disease is a common driver of adult hyperthyroidism with incidence estimates for hyperthyroidism rising around 1 to 2 percent per year in the United States and Graves-specific rates reported at roughly 30 to 40 per 100,000 person-years in Denmark and about 42 per 100,000 person-years in Taiwan, while the striking female predominance of about 7 to 8 times higher risk underscores its broad population impact.
02 · Category
Risk Factors9 stats
01
In pregnancy, Graves disease can cause fetal/neonatal thyrotoxicosis risk; TRAb levels above guideline thresholds correlate with higher riskhttps://www.ncbi.nlm.nih.gov/books/NBK279113/
02
In a systematic review, smoking increased the risk of Graves ophthalmopathy by about 2–3x compared with non-smokershttps://pubmed.ncbi.nlm.nih.gov/24429216/
03
TRAb positivity is reported in ~90% or more of patients with Graves disease in clinical series, supporting its role as a key disease markerhttps://www.ncbi.nlm.nih.gov/books/NBK482370/
04
Women with Graves disease have higher risk for relapse after initial antithyroid drug therapy than men, with sex differences reported across trialshttps://www.ncbi.nlm.nih.gov/books/NBK537047/
05
Risk of Graves ophthalmopathy is increased by radioactive iodine treatment, with studies reporting higher rates compared with some alternativeshttps://pubmed.ncbi.nlm.nih.gov/19843901/
06
Elevated thyroid peroxidase antibodies (TPOAb) are detected in a substantial fraction of Graves patients, with meta-analyses reporting frequencies often above 50%https://pubmed.ncbi.nlm.nih.gov/19777332/
07
Genetic variants in HLA and other immune loci contribute to Graves disease susceptibility; polygenic risk scores can explain a measurable fraction of risk in studied cohortshttps://pubmed.ncbi.nlm.nih.gov/31142816/
08
Selenium supplementation trials have shown reduced risk or severity of Graves ophthalmopathy progression in some meta-analyses (effect size reported in pooled analyses)https://pubmed.ncbi.nlm.nih.gov/31394290/
09
After thyroidectomy for Graves disease, hypocalcemia incidence depends on surgical factors; large reviews report temporary hypocalcemia in several percent to >10% rangehttps://pubmed.ncbi.nlm.nih.gov/26070244/
Interpretation
Risk Factors Interpretation
Across key risk factors for Graves disease, several signals stand out such as TRAb positivity in about 90% or more of patients and smoking increasing Graves ophthalmopathy risk roughly 2 to 3 times, while pregnancy risk rises with TRAb above guideline thresholds.
03 · Category
Economics & Burden12 stats
01
Antithyroid drugs require ongoing lab monitoring; guideline-based schedules imply recurring lab costs measured per monitoring intervalhttps://www.ncbi.nlm.nih.gov/books/NBK279133/
02
A US Medicare study reported that total costs for Graves disease management were substantial and included medication, outpatient visits, and laboratory monitoringhttps://pubmed.ncbi.nlm.nih.gov/25147704/
03
In a claims-based analysis, patients with hyperthyroidism/Graves incurred higher all-cause healthcare costs than matched controls, with differences measured in dollars per patient-yearhttps://pubmed.ncbi.nlm.nih.gov/21801679/
04
The global prevalence of thyroid eye disease (TED) among Graves patients has been estimated around 25–30%, translating into a large disability and cost burdenhttps://pubmed.ncbi.nlm.nih.gov/28910465/
05
Quality-of-life studies show that active Graves ophthalmopathy can reduce utility values; published health economic models quantify QALY losses relative to baselinehttps://pubmed.ncbi.nlm.nih.gov/22447716/
06
In health economic evaluations, teprotumumab has been modeled with incremental cost per QALY gained versus comparators, using trial and utility inputshttps://pubmed.ncbi.nlm.nih.gov/36332253/
07
Economic burden analyses estimate productivity loss from thyroid eye disease as a measurable share of overall societal costshttps://pubmed.ncbi.nlm.nih.gov/26152383/
08
Graves ophthalmopathy can cause measurable work impairment; observational studies quantify reductions in work capacity and time missedhttps://pubmed.ncbi.nlm.nih.gov/21480647/
09
Long-term follow-up after radioactive iodine commonly results in lifelong levothyroxine use; levothyroxine cost is included in chronic management cost modelshttps://pubmed.ncbi.nlm.nih.gov/26848249/
10
Patients with Graves disease experience relapse after medication withdrawal; economic models incorporate relapse-driven additional treatments and monitoringhttps://pubmed.ncbi.nlm.nih.gov/24703023/
11
Serious adverse events like agranulocytosis and hepatotoxicity are rare but can generate high downstream healthcare costs; pharmacovigilance analyses quantify event frequencieshttps://pubmed.ncbi.nlm.nih.gov/19319261/
12
Burden of thyroid disease in the US (including hyperthyroidism) is measurable in administrative datasets; analyses show substantial annual healthcare utilizationhttps://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2774883
Interpretation
Economics & Burden Interpretation
Across economics and burden, Graves disease and its eye complications create an ongoing and measurable cost load, from recurring lab monitoring and higher dollars per patient year in claims studies to an estimated 25 to 30% of patients developing thyroid eye disease with documented QALY losses and productivity impacts.
04 · Category
Treatment Outcomes9 stats
01
A Cochrane review reported that continuing antithyroid drugs longer increases remission probabilities compared with shorter courses, with relapse reduced in longer-duration strategieshttps://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003434.pub4/full
02
Radioactive iodine therapy is associated with long-term euthyroidism in many patients; studies commonly report ~80% needing eventual levothyroxine within years due to hypothyroidismhttps://pubmed.ncbi.nlm.nih.gov/25041662/
03
Radioactive iodine dose regimens typically achieve effectiveness with single or adjusted dosing; trial evidence reports high rates of thyrotropin suppression resolutionhttps://pubmed.ncbi.nlm.nih.gov/28300909/
04
In the teprotumumab Phase 3 study, 68% of treated patients achieved a proptosis response at Week 24 versus 20% with placebohttps://www.nejm.org/doi/full/10.1056/NEJMoa2000818
05
In a randomized trial of rituximab for Graves ophthalmopathy, response rates were compared across arms and some pooled evidence shows measurable benefit for ocular outcomeshttps://pubmed.ncbi.nlm.nih.gov/30740416/
06
For Graves ophthalmopathy severity, corticosteroids can reduce active inflammation; response proportions vary, but trials and reviews commonly report improvements in clinical activity scores over weekshttps://pubmed.ncbi.nlm.nih.gov/27068209/
07
Surgery for stable Graves ophthalmopathy improves functional outcomes in many cases; success rates for orbital decompression are commonly reported in the literature above 70–90% for targeted endpointshttps://pubmed.ncbi.nlm.nih.gov/29973933/
08
Radioactive iodine plus glucocorticoid prophylaxis reduces the risk of worsening ophthalmopathy; meta-analyses report a relative risk reduction in those given prophylaxishttps://pubmed.ncbi.nlm.nih.gov/23901510/
09
Euthyroidism after radioiodine often leads to hypothyroidism; cohort studies frequently report hypothyroidism occurrence in the majority within 5–10 yearshttps://pubmed.ncbi.nlm.nih.gov/18678641/
Interpretation
Treatment Outcomes Interpretation
Across treatment outcomes in Graves disease, longer antithyroid drug courses and active ophthalmopathy therapies show clearer, higher response rates, such as teprotumumab improving proptosis in 68% at Week 24 versus 20% on placebo, while radioactive iodine often delivers long-term control but leads to hypothyroidism in most patients over 5 to 10 years, underscoring the tradeoff clinicians manage when choosing a strategy.
05 · Category
Guidelines & Diagnostics5 stats
01
European Thyroid Association guidelines recommend TRAb measurements for assessment of remission and relapse risk after antithyroid drugshttps://pubmed.ncbi.nlm.nih.gov/24043244/
02
Imaging with radioactive iodine uptake or thyroid scintigraphy helps confirm diagnosis when antibody testing is inconclusive; uptake patterns differentiate Graves from other causeshttps://www.ncbi.nlm.nih.gov/books/NBK279109/
03
Ultrasound with Doppler can show increased vascularity in Graves disease; clinical guidance cites this as supportive evidencehttps://www.ncbi.nlm.nih.gov/books/NBK493234/
04
Clinical Activity Score (CAS) is used to quantify active Graves ophthalmopathy; scores ≥3/7 indicate active disease in commonly used schemeshttps://pubmed.ncbi.nlm.nih.gov/11487554/
05
EULAR/ENDO and endocrine society guidance support TRAb testing and monitoring because TRAb predicts relapse after antithyroid drug withdrawalhttps://pubmed.ncbi.nlm.nih.gov/25865502/
Interpretation
Guidelines & Diagnostics Interpretation
Guidelines & Diagnostics emphasize that tests like TRAb and supportive imaging are central throughout care, with TRAb repeatedly recommended for remission and relapse risk and active Graves ophthalmopathy flagged when CAS is at least 3 out of 7.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Rachel Svensson. (2026, February 13). Graves Disease Statistics. Gitnux. https://gitnux.org/graves-disease-statistics
MLA
Rachel Svensson. "Graves Disease Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/graves-disease-statistics.
Chicago
Rachel Svensson. 2026. "Graves Disease Statistics." Gitnux. https://gitnux.org/graves-disease-statistics.
Sources & references
44 datasets cited across this report
+39 additional datasets cited (not shown individually)